BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Kolltan Pharmaceuticals Inc. 

300 George Street
Suite 530
New Haven  Connecticut  06511  U.S.A.
Phone: 203-773-3000 Fax: 203-773-1300


SEARCH JOBS

Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.


 Key Statistics


Email: info@kolltan.com
Ownership: Private

Web Site: Kolltan Pharmaceuticals Inc.
Employees:
Symbol: 
 









 Company News
Kolltan Pharmaceuticals Inc. Expands Company's Board Of Directors 4/16/2014 6:37:36 AM    More...
Kolltan Pharmaceuticals Inc. Hauls In $60 Million Series D Financing 3/26/2014 6:56:09 AM    More...
Kolltan Pharmaceuticals Inc. Initiates Phase 1 Study Of KTN3379, A Dual-Mechanism Anti-Erbb3 Monoclonal Antibody 1/21/2014 9:22:17 AM    More...
Kolltan Pharmaceuticals Inc. Licenses Novel Anti-KIT Antibodies And Related Intellectual Property From The University of Toronto 12/6/2013 9:45:53 AM    More...
Kolltan Pharmaceuticals Inc. Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer 9/9/2013 7:03:15 AM    More...
Kolltan Pharmaceuticals Inc. Enters into License and Option Agreement With MedImmune (AZN) 7/29/2013 9:29:38 AM    More...
Kolltan Pharmaceuticals Inc. and The Children's Hospital of Philadelphia to Initiate Collaboration in Pediatric Neuroblastoma 7/18/2013 10:13:03 AM    More...
Kolltan Pharmaceuticals Inc. Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer 4/23/2012 7:25:59 AM    More...
Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team 8/18/2009 9:31:04 AM    More...
Kolltan Pharmaceuticals (JOBS) Adds $5 Million to Close Series A Financing 8/18/2009 6:35:51 AM    More...
12

//-->